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Introduction
Cryopyrin-associated periodic syndromes (CAPS) is a
group of rare monogenetic autoinflammatory disorders.
Evidence-based guidelines are lacking and management is
mostly based on physician’s experience. Consequently,
treatment regimens differ throughout Europe. In 2012, a
European initiative called SHARE (Single Hub and Access
point for pediatric Rheumatology in Europe) was launched
to optimize and disseminate diagnostic and management
regimens in Europe for children and young adults with
rheumatic diseases.
Objectives
One of the aims of SHARE was to provide evidence based
recommendations for management (treatment and moni-
toring) of CAPS.
Methods
Evidence based recommendations were developed using
the European League Against Rheumatism (EULAR) stan-
dard operating procedure. An expert committee was insti-
tuted, consisting of pediatric and adult rheumatologists.
The expert committee defined search terms for the sys-
tematic literature review. Two independent experts scored
articles for validity and level of evidence. Recommenda-
tions derived from the literature were evaluated by an
online survey. Those with less than 80% agreement on the
online survey or with relevant comments of the experts
were reformulated. Subsequently, all recommendations
were discussed at a consensus meeting using Nominal
Group Technique. Recommendations were accepted if
more than 80% agreement was reached.
Results
The literature search yielded 1698 articles, of which
25 papers on treatment were considered relevant and
therefore scored for validity and level of evidence. Seven-
teen were scored valid and used in the formulation of the
recommendations. Fifteen recommendations were sug-
gested in the online survey and discussed during the con-
sensus meeting. Six general recommendations on
management, five for monitoring and four for treatment
were accepted with more than 80% agreement. Topics
covered are the following: the multidisciplinary team,
treatment goals, adjunctive therapies, psychosocial support
and vaccinations [general recommendations], monitoring
frequency, minimal assessments in all CAPS patients and
monitoring of severe phenotypes [monitoring] and IL-1
blockade, NSAIDs and/or glucocorticoids during attacks
and DMARDS/biologicals other than IL-1 blockade
[treatment].
Conclusion
The SHARE initiative provides recommendations for the
management of CAPS and thereby facilitates improve-
ment and uniformity of care throughout Europe.1Laboratory for Translational Immunology, University Medical Center Utrecht,
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